

525,166

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



22 FEB 2005



(43) International Publication Date
4 March 2004 (04.03.2004)

PCT

(10) International Publication Number
WO 2004/017975 A1

(51) International Patent Classification⁷: **A61K 31/519**, (74) Common Representative: **RANBAXY LABORATORIES LIMITED**; c/o Deshmukh, Jay, R., 600 College Road East, Suite 2100, Princeton, NJ 08540 (US).

(21) International Application Number:
PCT/IB2003/003529

(22) International Filing Date: 25 August 2003 (25.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
859/DEL/2002 23 August 2002 (23.08.2002) IN

(71) Applicant (for all designated States except US): **RANBAXY LABORATORIES LIMITED** [IN/IN]; 19, Nehru Place, New Delhi 110 019, Delhi (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GOGIA, Ashish** [IN/IN]; K-70, Krishnan Nagar, New Delhi 110 051, Delhi (IN). **ROY, Sunilendu, Bhushan** [IN/IN]; Bungalow #7, Row House, Lokpuram, Thane (West), Mumbai 400 601, Maharashtra (IN). **MALIK, Rajiv** [IN/IN]; 6-B, Pocket-B, Gangotri Enclave, Alaknanda, New Delhi 110 019, Delhi (IN).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/017975 A1

(54) Title: STABLE AQUEOUS SOLUTIONS OF RISPERIDONE AND METHODS FOR THEIR PREPARATION

(57) Abstract: The technical field of the present invention relates to stable aqueous solution of risperidone for oral administration; and process for preparation thereof.

STABLE AQUEOUS SOLUTIONS OF RISPERIDONE AND METHODS FOR THEIR PREPARATION

5

FIELD OF THE INVENTION

The technical field of the present invention relates to stable aqueous solution of risperidone for oral administration; and process for preparation thereof.

BACKGROUND OF THE INVENTION

Risperidone, chemically 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one belongs to a new chemical class of antipsychotic agents. It is indicated for the management of the manifestations of psychotic disorders. Oral solutions of risperidone are commercially marketed by Janssen Pharma under the trade name Risperdal®.

U.S. Patent No. 4,804,663 discloses 3-piperidinyl-1,2-benzosoxazoles and their pharmaceutically acceptable acid addition salts having useful antipsychotic activity. It also exemplifies an oral solution of the above compounds with preservatives, tartaric acid, sodium-saccharin, flavors, and the polyhydric alcohols such as sorbitol and glycerol.

However, as disclosed in U.S. Patent No. 5,453,425, comparable solutions in which the benzisoxazole derivative was risperidone exhibited an unsatisfactory physicochemical stability. The instability was found to be caused due to sorbitol, which accelerated the decomposition of risperidone upon storage at elevated temperatures. A similar observation was made with maltitol, suggesting that risperidone is incompatible with polyhydric alcohols.

The above incompatibilities have been addressed in the prior art by avoiding the use of polyhydric alcohols in pharmaceutical compositions of risperidone. For example, U.S. Patent Nos. 5,453,425 and 5,616,587 disclose aqueous solutions of risperidone essentially free of polyhydric alcohols, such as mannitol, fructose, sucrose, maltose and the like.

Polyhydric alcohols have several advantages and form a class of one of the most widely used sweeteners or bitter taste-masking agents in oral liquid dosage forms. Hence,

one would generally desire to have the option of using polyhydric alcohols as sweeteners in forming stable liquid dosage forms of risperidone.

SUMMARY OF THE INVENTION

In one general aspect there is provided an aqueous solution of risperidone. The
5 aqueous solution includes water; a therapeutically effective amount of risperidone or a pharmaceutically acceptable free risperidone base or acid addition salt of risperidone; one or more polyhydric alcohols; and one or more buffering agents configured to maintain the pH in the range of about 2 to about 6.

Embodiments of the solution may include one or more of the following features.

- 10 For example, the addition salt may be selected from one or more of salts of risperidone with inorganic acids comprising hydrochloric, hydrobromic, sulfuric, nitric, and phosphoric acids; or organic acids comprising acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methane-sulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, and pamoic acids. The one or more polyhydric alcohols may be one or more of monosaccharides, disaccharides and sugars. The monosaccharide may be one or both of glucose (dextrose) and fructose (levulose). The disaccharide may be one or more of sucrose, lactose, maltose and cellobiose. The disaccharide may be sucrose. The sugars may be one or more of ribose, glycerine, sorbitol, xylitol, maltitol, erythritol, inositol,
15 lactitol monohydrate, propylene glycol, galactose, mannose, xylose, rhamnose, glutaraldehyde, invert sugars, mannitol, polyethylene glycol and glycerol. The sugar may be sorbitol.
20

The aqueous solution may further include an antioxidant. The antioxidant may be one or more of antioxidants, reducing agents and antioxidant synergist. The antioxidants may be one or more of acetylcysteine, alpha tocopherol acetate, d- alpha tocopherol, dl-alpha tocopherol, ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), cysteine, cysteine hydrochloride and propyl gallate. The reducing agent may be one or more of ascorbic acid, calcium ascorbate, calcium bisulphite, calcium sulphite, ascorbic acid, isoascorbic acid, potassium metabisulphite, sodium ascorbate,
25 sodium bisulphite, sodium metabisulphite, sodium sulphite, sodium thiosulphate and thioglycerol. The antioxidant synergist may be one or more of citric acid, edetic acid
30

(EDTA) and its salts, hydroxyquinoline sulphate, phosphoric acid, sodium citrate and tartaric acid.

The solution may further include one or more pharmaceutically acceptable additives. The one or more pharmaceutically acceptable additives may be one or more of preservatives, solubilizers, viscosity enhancing agents, colors and flavors. The preservative may be one or more of benzoic acid, sorbic acid, methyl paraben or salts thereof, propyl paraben or salts thereof, benzyl alcohol and benzylalkonium chloride. The buffering agent may be an acid-base combination. The acid may be one or more of succinic, tartaric, lactic, or citric acid and base is sodium hydroxide or disodium hydrogen phosphate. The acid may be tartaric acid and base may be sodium hydroxide.

The flavors may be one or more of vanilla, cherry, raspberry, black currant, strawberry, caramel chocolate, Mint Cool and Fantasy flavors.

In another general aspect there is provided a process for the preparation of an aqueous solution. The process includes mixing water, a therapeutically effective amount of risperidone or a pharmaceutically acceptable free risperidone base or acid addition salt of risperidone, one or more polyhydric alcohols; and one or more buffering agents configured to maintain the pH in the range of about 2 to about 6.

Embodiments of the process may include one or more of the following features. For example, the addition salt may be selected from one or more of salts of risperidone with inorganic acids comprising hydrochloric, hydrobromic, sulfuric, nitric, and phosphoric acids; or organic acids comprising acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, and pamoic acids. The one or more polyhydric alcohols may be one or more of monosaccharides, disaccharides and sugars. The monosaccharide may be one or both of glucose (dextrose) and fructose (levulose). The disaccharide may be one or more of sucrose, lactose, maltose and cellobiose. The disaccharide may be sucrose. The sugars may be one or more of ribose, glycerine, sorbitol, xylitol, maltitol, erythritol, inositol, lactitol monohydrate, propylene glycol, galactose, mannose, xylose, rhamnose, glutaraldehyde, invert sugars, mannitol, polyethylene glycol and glycerol. The sugar may be sorbitol.

The aqueous solution may further include an antioxidant. The antioxidant may be one or more of antioxidants, reducing agents and antioxidant synergist. The antioxidants may be one or more of acetylcysteine, alpha tocopherol acetate, d- alpha tocopherol, dl-alpha tocopherol, ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), cysteine, cysteine hydrochloride and propyl gallate. The reducing agent may be one or more of ascorbic acid, calcium ascorbate, calcium bisulphite, calcium sulphite, ascorbic acid, isoascorbic acid, potassium metabisulphite, sodium ascorbate, sodium bisulphite, sodium metabisulphite, sodium sulphite, sodium thiosulphate and thioglycerol. The antioxidant synergist may be one or more of citric acid, edetic acid (EDTA) and its salts, hydroxyquinoline sulphate, phosphoric acid, sodium citrate and tartaric acid.

The solution may further include one or more pharmaceutically acceptable additives. The one or more pharmaceutically acceptable additives may be one or more of preservatives, solubilizers, viscosity enhancing agents, colors and flavors. The preservative may be one or more of benzoic acid, sorbic acid, methyl paraben or salts thereof, propyl paraben or salts thereof, benzyl alcohol and benzylalkonium chloride. The buffering agent may be an acid-base combination. The acid may be one or more of succinic, tartaric, lactic, or citric acid and base is sodium hydroxide or disodium hydrogen phosphate. The acid may be tartaric acid and base may be sodium hydroxide.

The flavors may be one or more of vanilla, cherry, raspberry, black currant, strawberry, caramel chocolate, Mint Cool and Fantasy flavors.

In another general aspect, there is provided a method for the management or treatment of the manifestations of psychotic disorders in a mammal. The method includes administering an aqueous solution comprising water; a therapeutically effective amount of risperidone or a pharmaceutically acceptable free risperidone base or acid addition salt of risperidone; one or more polyhydric alcohols; and one or more buffering agents configured to maintain the pH in the range of about 2 to about 6.

Embodiments of the method may include one or more of the following features. For example, the addition salt may be selected from one or more of salts of risperidone with inorganic acids comprising hydrochloric, hydrobromic, sulfuric, nitric, and phosphoric acids; or organic acids comprising acetic, propanoic, hydroxyacetic, lactic,

pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, and pamoic acids. The one or more polyhydric alcohols may be one or more of monosaccharides, disaccharides and sugars. The monosaccharide may be one or both of glucose (dextrose) and fructose (levulose). The disaccharide may be one or more of sucrose, lactose, maltose and cellobiose. The disaccharide may be sucrose. The sugars may be one or more of ribose, glycerine, sorbitol, xylitol, maltitol, erythritol, inositol, lactitol monohydrate, propylene glycol, galactose, mannose, xylose, rhamnose, glutaraldehyde, invert sugars, mannitol, polyethylene glycol and glycerol. The sugar may 10 be sorbitol.

The aqueous solution may further include an antioxidant. The antioxidant may be one or more of antioxidants, reducing agents and antioxidant synergist. The antioxidants may be one or more of acetylcysteine, alpha tocopherol acetate, d- alpha tocopherol, dl-alpha tocopherol, ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated 15 hydroxytoluene (BHT), cysteine, cysteine hydrochloride and propyl gallate. The reducing agent may be one or more of ascorbic acid, calcium ascorbate, calcium bisulphite, calcium sulphite, ascorbic acid, isoascorbic acid, potassium metabisulphite, sodium ascorbate, sodium bisulphite, sodium metabisulphite, sodium sulphite, sodium thiosulphate and thioglycerol. The antioxidant synergist may be one or more of citric acid, edetic acid 20 (EDTA) and its salts, hydroxyquinoline sulphate, phosphoric acid, sodium citrate and tartaric acid.

The solution may further include one or more pharmaceutically acceptable additives. The one or more pharmaceutically acceptable additives may be one or more of preservatives, solubilizers, viscosity enhancing agents, colors and flavors. The 25 preservative may be one or more of benzoic acid, sorbic acid, methyl paraben or salts thereof, propyl paraben or salts thereof, benzyl alcohol and benzylalkonium chloride. The buffering agent may be an acid-base combination. The acid may be one or more of succinic, tartaric, lactic, or citric acid and base is sodium hydroxide or disodium hydrogen phosphate. The acid may be tartaric acid and base may be sodium hydroxide.

30 The flavors may be one or more of vanilla, cherry, raspberry, black currant, strawberry, caramel chocolate, Mint Cool and Fantasy flavors.

The details of one or more embodiments of the inventions are set forth in the description below. Other features, objects, and advantages of the inventions will be apparent from the description and the claims.

DETAILED DESCRIPTION OF THE INVENTION

5 The inventors have now discovered that stable aqueous solutions of risperidone can be prepared using polyhydric alcohols. U.S. Patent No. 4,804,663, above, describes an aqueous solution of risperidone with a small amount of water (less than 30% v/v). By experimenting in our laboratory the inventors have discovered that a stable aqueous solution of risperidone containing polyhydric alcohols may be prepared by reducing the
10 solid content and increasing the water concentration of the aqueous solution. The stability may further be improved by incorporating small amounts of an antioxidant. This was confirmed by the accelerated stability data generated at 80°C over a period of 4 weeks (Table 1). The solution had excellent palatability and could be administered as such, without any further dilution.

15 The term "stable" as used herein refers to a solution wherein, after storage for a period up to 4 weeks at a temperature of 80° C or below, the residual amount of risperidone is at least 80% of the initial risperidone concentration.

20 The term "risperidone" as used herein refers to the free risperidone base as well as pharmaceutically acceptable acid addition salts thereof. Specific examples of acid addition salts include salts with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and other similar or related inorganic acids; or with organic acids such as acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methane-sulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the
25 like acids. The amount (w/v) of risperidone in the solution may vary from about 0.01% to about 1%, preferably from about 0.02% to about 0.5%, most preferably from about 0.05% to about 0.25%, and in particular is 0.1% (1mg/1ml).

30 Examples of polyhydric alcohols that may be used as sweeteners include monosaccharides such as glucose (dextrose) and fructose (levulose); disaccharides such as sucrose, lactose, maltose, and cellobiose; other sugars such as ribose, glycerine, sorbitol, xylitol, maltitol, erythritol, inositol, lactitol monohydrate, propylene glycol, galactose,

mannose, xylose, rhamnose, glutaraldehyde, invert sugars, mannitol, polyethylene glycol, glycerol or mixtures thereof. In particular, sucrose and/or sorbitol may be used as sweeteners in an amount (w/v) varying from about 0.01% to about 50%.

Using polyhydric alcohols, such as sorbitol, as a sweetener has many advantages, 5 as these provide bulk and sweetness with a clean, cool pleasant taste. Sorbitol also provides one-third fewer calories than sugar. It is an excellent humectant, texturizing and anti-crystallizing agent. Moreover, polyhydric alcohols are resistant to metabolism by oral bacteria, which break down sugars, and starches that releases acids that may lead to cavities or erode tooth enamel. They are, therefore, non-carcinogenic.

10 Sorbitol is slowly absorbed, and, consequently, when sorbitol is ingested, the rise in blood glucose and the insulin response which is associated with the ingestion of glucose, is significantly reduced. Therefore Sorbitol can be used as an alternative to sugar for people with diabetes. Sorbitol also has been affirmed as GRAS (Generally Recognized As Safe) by the U.S. Food and Drug Administration and is approved for use by the 15 European Union and numerous countries around the world, including Australia, Canada and Japan.

Sorbitol offers advantages when used in pharmaceutical formulations. For example, sorbitol is very stable, chemically inert and can withstand high temperatures. The commercially available risperidone aqueous solution "Risperdal" has disadvantages, 20 such as the requirement that it be diluted with 100 ml of beverage before consuming. This may be due to the necessity of diluting the bitter taste of risperidone. However, polyhydric alcohols, such as sorbitol, mannitol, fructose, sucrose, and maltose can be used as a bulk sweetener to give a palatable aqueous solution that can be administered without any dilution. Consequently, the use of polyhydric alcohols, particularly sorbitol, which 25 are highly effective as sweeteners help in better taste masking of the bitter taste of risperidone and thereby do not necessitate dilution during administration

Antioxidants used for enhancing the stability of risperidone solution include 30 compounds from any of the three general classes of antioxidant: true antioxidants, reducing agents, and antioxidant synergist. Examples of suitable true antioxidants include acetylcysteine, alpha tocopherol acetate, d- alpha tocopherol, dl- alpha tocopherol, ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT),

cysteine, cysteine hydrochloride, propyl gallate and the like. Examples of suitable reducing agents include ascorbic acid, calcium ascorbate, calcium bisulphite, calcium sulphite, isoascorbic acid, potassium metabisulphite, sodium ascorbate, sodium bisulphite, sodium metabisulphite, sodium sulphite, sodium thiosulphate, thioglycerol and the like.

- 5 Examples of suitable antioxidant synergists include citric acid and edetic acid (EDTA) and its salts, including disodium EDTA, hydroxyquinoline sulphate, phosphoric acid, sodium citrate, tartaric acid and the like.

In particular, antioxidants are used that are safe for oral ingestion and have sufficient solubility in the solution to make a stable, single-phase composition which is 10 stable over a wide range of temperatures and pH values and is compatible with other components of the solution. Mixtures of two or more of the antioxidants may also be used. The amount (w/v) of antioxidant may vary from about 0.01% to about 5.0%.

Besides the above, the stable aqueous solution of risperidone may also include one or more pharmaceutically acceptable additives such as antimicrobial preservatives, 15 buffering agents, solubilizers, viscosity enhancing agents, colors, flavors and the like.

Examples of suitable preservatives include benzoic acid, sorbic acid, and methyl paraben or salts thereof, propyl paraben or salts thereof, benzyl alcohol and benzylalkonium chloride. The concentration (w/v) of the preservative may range from about 0.05% to about 2%.

20 Examples of suitable solubilizers include co-solvents, complexing agents, surfactants wetting agents and the like.

Examples of suitable viscosity enhancing agents include hydroxypropyl methylcellulose (some forms of which are available from Dow Chemical, Midland, Mich. USA under the METHOCEL trademark), hydroxpropyl cellulose and the like.

25 Examples of suitable colors and flavors include all FDA approved colors or flavors suitable for oral use. Specific examples of flavors include vanilla, cherry, raspberry, black currant, strawberry, Caramel Chocolate, Mint Cool, Fantasy flavors and the like.

If desired, the pH of the stable risperidone solution may be adjusted from between about 2 to about 6, with the use of buffering agents. Buffering agents are acid-base

combinations such as succinic, tartaric, lactic, or citric acid with sodium hydroxide or disodium hydrogen phosphate.

In one of the embodiments a stable aqueous risperidone solution may be prepared by:

- 5 (a) dissolving preservatives, stabilizers and acid component of the buffering system in hot purified water;
- (b) cooling the solution;
- (c) dissolving risperidone under continuous stirring in the cooled solution;
- (d) adding one or more sweeteners;
- 10 (e) adding one or more colors and/or flavors; and
- (f) adjusting the pH with the basic component of the buffering system and making up the volume.

The following examples are intended to illustrate the scope of the present invention in all its aspects but not to limit it thereto.

15

Example 1

Ingredients	Quantity
Risperidone	1mg/ml
Benzoic Acid	1mg/ml
Tartaric Acid	7.5mg/ml
Sodium hydroxide	2 mg/ml
Sorbitol Solution (70%)	10%w/v
Artificial Creme De Vanilla Flavor	0.15%v/v
Artificial Raspberry Flavor	0.5% v/v
Purified water	q.s to 1 ml

Process:

1. Benzoic acid was dissolved in purified water at 60°C.

2. Tartaric acid was dissolved in the solution of step 1, and then cooled to a temperature of less than 30°C.
3. Risperidone was then dissolved in the cooled solution under continuous stirring.
4. Sorbitol solution (70%) was mixed with the bulk solution of step 3, followed by the addition of Artificial Creme De Vanilla Flavor and Artificial Raspberry Flavor.
5. The pH of the solution of step 4 was then adjusted to between about 3 and about 4 with sodium hydroxide solution, followed by volume makeup using purified water.
6. The bulk of step 5 was then filtered through a 5µm polypropylene filter and filled into suitable containers.

10

Example 2

Ingredients	Quantity
Risperidone	1mg/ml
Benzoic Acid	1mg/ml
Tartaric Acid	7.5mg/ml
Sodium hydroxide	2 mg/ml
Sorbitol Solution (70%)	10%w/v
EDTA disodium	1mg/ml
Artificial Creme De Vanilla Flavor	0.15%v/v
Artificial Raspberry Flavor	0.5% v/v
Purified water	q.s to 1 ml

Process:

1. Benzoic acid and EDTA disodium were dissolved in purified water at 60°C.
2. Tartaric acid was dissolved in the solution of step 1, and then cooled to a temperature of less than 30°C.
3. Risperidone was then dissolved in the cooled solution under continuous stirring.

4. Sorbitol solution (70%) was mixed with the bulk solution of step 3, followed by the addition of Artificial Creme De Vanilla Flavor and Artificial Raspberry Flavor.
5. The pH of the solution of step 4 was then adjusted to between about 3 and about 4 with sodium hydroxide solution, followed by volume makeup using purified water.
6. The bulk of step 5 was then filtered through a 5µm polypropylene filter and filled into suitable containers.

The above solutions when subjected to accelerated stability, i.e., at a temperature of 80° C for a period up to 4 weeks, showed excellent stability. This is clearly evident from the data given in Table-1.

Table 1. Accelerated stability data of risperidone solutions containing sorbitol generated at 80°C for a period of four weeks

Formulation	Risperidone concentration (%)	
	Initial	After 4 weeks at 80°C
Solution with 70% sorbitol	100	<80
Solution with 10% sorbitol (Example 1)	99.90	88.60
Solution with 10% sorbitol and EDTA di-sodium (Example 2)	102.50	96.20

15 While several particular forms of the inventions have been described, it will be apparent that various modifications and combinations of the inventions detailed in the text can be made without departing from the spirit and scope of the inventions. For example, although the examples above are directed to application of the inventive concepts described herein to risperidone as the active pharmaceutical ingredient, these concepts can 20 be applied to other active antipsychotic ingredients, such as 1,2-benzisoxazol-3-yl derivatives. Finally, it is contemplated that any single feature or any combination of optional features of the inventive variations described herein may be specifically excluded

from the claimed inventions and be so described as a negative limitation. Accordingly, it is not intended that the inventions be limited, except as by the appended claims.

WE CLAIM:

1. 1. An aqueous solution of risperidone, the aqueous solution comprising:
 2. water;
 3. a therapeutically effective amount of risperidone or a pharmaceutically acceptable free risperidone base or acid addition salt of risperidone;
 5. one or more polyhydric alcohols; and
 6. one or more buffering agents configured to maintain the pH in the range of about 3 to about 4..
1. 2. The aqueous solution of claim 1, wherein the addition salt is selected from one or more of salts of risperidone with inorganic acids comprising hydrochloric, hydrobromic, sulfuric, nitric, and phosphoric acids; or organic acids comprising acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methane-sulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, and pamoic acids.
1. 3. The aqueous solution of claim 1 wherein the one or more polyhydric alcohols comprises one or more of monosaccharides, disaccharides and sugars.
1. 4. The aqueous solution of claim 3 wherein the monosaccharide comprises one or both of glucose (dextrose) and fructose (levulose).
1. 5. The aqueous solution of claim 3 wherein the disaccharide comprises one or more of sucrose, lactose, maltose and cellobiose.
1. 6. The aqueous solution of claim 3 wherein the disaccharide comprises sucrose.
1. 7. The aqueous solution of claim 3 wherein the sugars comprise one or more of ribose, glycerine, sorbitol, xylitol, maltitol, erythritol, inositol, lactitol monohydrate, propylene glycol, galactose, mannose, xylose, rhamnose, glutaraldehyde, invert sugars, mannitol, polyethylene glycol and glycerol.
1. 8. The aqueous solution of claim 3 wherein the sugar comprises sorbitol.
1. 9. The aqueous solution of claim 1 wherein the aqueous solution further comprises an antioxidant.

1 10. The aqueous solution of claim 9 wherein the antioxidant comprises one or more of
2 antioxidants, reducing agents and antioxidant synergist.

1 11. The aqueous solution of claim 10 wherein the antioxidants comprises one or more
2 of acetylcysteine, alpha tocopherol acetate, d- alpha tocopherol, dl- alpha tocopherol,
3 ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT),
4 cysteine, cysteine hydrochloride and propyl gallate.

1 12. The aqueous solution of claim 10 wherein the reducing agent comprises one or
2 more of ascorbic acid, calcium ascorbate, calcium bisulphite, calcium sulphite, ascorbic acid,
3 isoascorbic acid, potassium metabisulphite, sodium ascorbate, sodium bisulphite, sodium metabisulphite,
4 sodium sulphite, sodium thiosulphate and thioglycerol.

1 13. The aqueous solution of claim 10 wherein the antioxidant synergist comprises one or more
2 of citric acid, edetic acid (EDTA) and its salts, hydroxyquinoline sulphate, phosphoric acid, sodium citrate
3 and tartaric acid.

1 14. The aqueous solution of claim 1 wherein the solution further comprises one or
2 more pharmaceutically acceptable additives.

1 15. The aqueous solution of claim 14 wherein the one or more pharmaceutically
2 acceptable additives comprise one or more of preservatives, solubilizers, viscosity
3 enhancing agents, colors and flavors.

1 16. The aqueous solution of claim 15 wherein the preservative comprises one or more
2 of benzoic acid, sorbic acid, methyl paraben or salts thereof, propyl paraben or salts
3 thereof, benzyl alcohol and benzylalkonium chloride.

1 17. The aqueous solution of claim 1 wherein the buffering agent comprises an acid-
2 base combination.

1 18. The aqueous solution of claim 17 wherein the acid comprises one or more of
2 succinic, tartaric, lactic, or citric acid and base is sodium hydroxide or disodium hydrogen
3 phosphate.

1 19. The aqueous solution of claim 17 wherein the acid is tartaric acid and base is
2 sodium hydroxide.

- 1 20. The aqueous solution of claim 15 wherein the flavors comprise one or more of
2 vanilla, cherry, raspberry, black currant, strawberry, caramel chocolate, Mint Cool and
3 Fantasy flavors.
- 1 21. A process for the preparation of an aqueous solution, the process comprising:
2 mixing water, a therapeutically effective amount of risperidone or a
3 pharmaceutically acceptable free risperidone base or acid addition salt of risperidone, one
4 or more polyhydric alcohols; and one or more buffering agents configured to maintain the
5 pH in the range of about 3 to about 4.
- 1 22. A method for the management or treatment of the manifestations of psychotic
2 disorders in a mammal, the method comprising administering an aqueous solution
3 comprising water; a therapeutically effective amount of risperidone or a pharmaceutically
4 acceptable free risperidone base or acid addition salt of risperidone; one or more
5 polyhydric alcohols; and one or more buffering agents configured to maintain the pH in
6 the range of about 3 to about 4.

INTERNATIONAL SEARCH REPORT

PCT/3/03529

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/519 A61K9/00 A61K47/10 A61K47/26

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 01652 A (JANSSEN) 25 January 1996 (1996-01-25) cited in the application claims example 1 ---	1-22
A	EP 0 196 132 A (JANSSEN) 1 October 1986 (1986-10-01) cited in the application claims 1,7-11 examples 10,11,14 ---	1-22
A	WO 94 25460 A (JANSSEN) 10 November 1994 (1994-11-10) claims example 2 ---	1-22 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

15 December 2003

23/12/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax: (+31-70) 340-3016

Authorized officer

Scarpone, U

INTERNATIONAL SEARCH REPORT

PCT/13/03529

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2001/042317 A1 (C.L.YARBOROUGH ET AL.) 22 November 2001 (2001-11-22) page 4, paragraph 58 page 5, paragraph 61 -----	1-22

INTERNATIONAL SEARCH REPORT

/IB 03/03529

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 22 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

PCT/EP 93/03529

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9601652	A	25-01-1996	US	5453425 A		26-09-1995
			US	5616587 A		01-04-1997
			AP	774 A		28-10-1999
			AT	206931 T		15-11-2001
			AU	684193 B2		04-12-1997
			AU	2927595 A		09-02-1996
			BG	63070 B1		30-03-2001
			BG	101106 A		29-08-1997
			BR	9508253 A		23-12-1997
			CA	2194564 A1		25-01-1996
			CY	2268 A		04-07-2003
			CZ	9700027 A3		16-07-1997
			DE	69523313 D1		22-11-2001
			DE	69523313 T2		27-06-2002
			DK	769965 T3		04-02-2002
			EE	9700009 A		15-08-1997
			WO	9601652 A1		25-01-1996
			EP	0769965 A1		02-05-1997
			ES	2165918 T3		01-04-2002
			FI	970109 A		10-01-1997
			HK	1010691 A1		08-03-2002
			HR	950397 A1		31-10-1997
			HU	76826 A2		28-11-1997
			IL	114525 A		20-06-1999
			JP	2872412 B2		17-03-1999
			JP	9511751 T		25-11-1997
			KR	212942 B1		02-08-1999
			NO	970051 A		07-01-1997
			NZ	289432 A		27-05-1998
			PL	318132 A1		12-05-1997
			PT	769965 T		29-04-2002
			RO	116778 B		29-06-2001
			RU	2161965 C2		20-01-2001
			SI	9500220 A		29-02-1996
			SK	2297 A3		10-09-1997
			TR	960766 A1		21-10-1996
			TW	420615 B		01-02-2001
			ZA	9505720 A		10-01-1997
EP 196132	A	01-10-1986	SG	119294 G		17-03-1995
			AU	579232 B2		17-11-1988
			AU	5529786 A		02-10-1986
			BG	60432 B2		31-03-1995
			CA	1256867 A1		04-07-1989
			CN	86101906 A , B		01-10-1986
			CY	1801 A		17-02-1995
			DK	143986 A		28-09-1986
			EP	0196132 A2		01-10-1986
			HK	108794 A		14-10-1994
			IE	58388 B1		08-09-1993
			JP	1908510 C		24-02-1995
			JP	6013511 B		23-02-1994
			JP	61221186 A		01-10-1986
			LU	88576 A9		21-03-1995
			SU	1468419 A3		23-03-1989
			US	4804663 A		14-02-1989
			AT	79379 T		15-08-1992
			CS	9103822 A3		13-05-1992

INTERNATIONAL SEARCH REPORT

PCT/13/03529

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 196132	A	DE 3686341 D1 DE 3686341 T2 ES 8705881 A1 FI 861328 A ,B, FI 893001 A GR 860800 A1 HU 42461 A2 IL 78250 A KR 9100165 B1 KR 9100437 B1 LT 2071 R3 LV 5043 A3 LV 5778 A4 NO 861230 A ,B, NZ 215462 A PH 24016 A PT 82254 A ,B SK 280125 B6 ZA 8602279 A	17-09-1992 14-01-1993 01-08-1987 28-09-1986 19-06-1989 21-07-1986 28-07-1987 12-05-1991 21-01-1991 25-01-1991 15-06-1993 10-06-1993 20-12-1996 29-09-1986 29-09-1988 09-02-1990 01-04-1986 06-08-1999 25-11-1987
WO 9425460	A 10-11-1994	AT 163418 T AU 675136 B2 AU 6721694 A BG 62004 B1 BG 100094 A CA 2160366 A1 CN 1121719 A ,B CY 2107 A CZ 9502706 A3 DE 69408666 D1 DE 69408666 T2 DK 697019 T3 WO 9425460 A1 EP 0697019 A1 ES 2113652 T3 FI 955166 A GR 3026028 T3 HK 1006059 A1 HU 72970 A2 IL 109448 A JP 8509482 T LV 12315 A LV 12315 B NO 954275 A NZ 266143 A PH 30476 A PL 311282 A1 RO 115955 B RU 2131428 C1 SG 47046 A1 SI 9420031 A ,B SK 131395 A3 US 5612346 A US 5723467 A ZA 9402909 A	15-03-1998 23-01-1997 21-11-1994 30-12-1998 31-05-1996 10-11-1994 01-05-1996 26-04-2002 17-01-1996 02-04-1998 18-06-1998 28-09-1998 10-11-1994 21-02-1996 01-05-1998 27-10-1995 30-04-1998 05-02-1999 28-06-1996 18-03-1997 08-10-1996 20-07-1999 20-03-2000 26-10-1995 26-07-1996 28-05-1997 05-02-1996 30-08-2000 10-06-1999 20-03-1998 31-08-1996 05-06-1996 18-03-1997 03-03-1998 26-10-1995
US 2001042317	A1 22-11-2001	NONE	